CN106573967B - 表皮生长因子受体基因的胞外域iii中的突变 - Google Patents

表皮生长因子受体基因的胞外域iii中的突变 Download PDF

Info

Publication number
CN106573967B
CN106573967B CN201480080780.3A CN201480080780A CN106573967B CN 106573967 B CN106573967 B CN 106573967B CN 201480080780 A CN201480080780 A CN 201480080780A CN 106573967 B CN106573967 B CN 106573967B
Authority
CN
China
Prior art keywords
seq
amino acid
egfr
mutations
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480080780.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN106573967A (zh
Inventor
A·巴尔代利
S·阿丽娜
C·蒙塔古特·维拉多特
J·阿尔巴内尔·梅斯特雷斯
A·罗维拉·格林
B·贝略西略·帕里西奥
A·达尔马塞斯·马塞谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Institut Hospital del Mar dInvestigacions Mediques IMIM
Original Assignee
Fundacio Institut Hospital del Mar dInvestigacions Mediques IMIM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Institut Hospital del Mar dInvestigacions Mediques IMIM filed Critical Fundacio Institut Hospital del Mar dInvestigacions Mediques IMIM
Publication of CN106573967A publication Critical patent/CN106573967A/zh
Application granted granted Critical
Publication of CN106573967B publication Critical patent/CN106573967B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201480080780.3A 2014-07-28 2014-12-30 表皮生长因子受体基因的胞外域iii中的突变 Active CN106573967B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382288.0 2014-07-28
EP14382288 2014-07-28
PCT/EP2014/079477 WO2016015788A1 (en) 2014-07-28 2014-12-30 Mutations in the extracellular domain iii of epidermal growth factor receptor gene

Publications (2)

Publication Number Publication Date
CN106573967A CN106573967A (zh) 2017-04-19
CN106573967B true CN106573967B (zh) 2022-02-18

Family

ID=51225482

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480080780.3A Active CN106573967B (zh) 2014-07-28 2014-12-30 表皮生长因子受体基因的胞外域iii中的突变

Country Status (8)

Country Link
US (2) US11015225B2 (cg-RX-API-DMAC7.html)
EP (2) EP3174896B1 (cg-RX-API-DMAC7.html)
JP (1) JP6905464B2 (cg-RX-API-DMAC7.html)
CN (1) CN106573967B (cg-RX-API-DMAC7.html)
BR (1) BR112017001474A2 (cg-RX-API-DMAC7.html)
CA (1) CA2954952C (cg-RX-API-DMAC7.html)
ES (1) ES2693080T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016015788A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016112064A2 (en) * 2015-01-06 2016-07-14 The Johns Hopkins University Response to egfr blockade
CN111499749B (zh) * 2020-03-13 2021-11-09 浙江大学 一种西妥昔单抗突变体及应用
CN115947823B (zh) * 2022-09-29 2024-05-03 江汉大学 一种用于筛选结合和/或激活egfr的有毒金属的表达蛋白及制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101501211A (zh) * 2004-03-31 2009-08-05 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
CN103717616A (zh) * 2011-08-03 2014-04-09 玛尔医学研究所基金会 表皮生长因子受体基因中的突变

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914269A (en) * 1997-04-04 1999-06-22 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of epidermal growth factor receptor expression
US9074204B2 (en) * 2011-05-20 2015-07-07 Fluidigm Corporation Nucleic acid encoding reactions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101501211A (zh) * 2004-03-31 2009-08-05 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
CN103717616A (zh) * 2011-08-03 2014-04-09 玛尔医学研究所基金会 表皮生长因子受体基因中的突变

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer;Clara Montagut et al.,;《Nature Medicine》;20120122;第18卷(第2期);221-223 *

Also Published As

Publication number Publication date
US20210262037A1 (en) 2021-08-26
BR112017001474A2 (pt) 2018-02-20
EP3174896B1 (en) 2018-08-22
US11015225B2 (en) 2021-05-25
CA2954952C (en) 2023-05-23
WO2016015788A1 (en) 2016-02-04
EP3174896A1 (en) 2017-06-07
JP2017522890A (ja) 2017-08-17
CA2954952A1 (en) 2016-02-04
US20170260250A1 (en) 2017-09-14
EP3428185A1 (en) 2019-01-16
JP6905464B2 (ja) 2021-07-21
CN106573967A (zh) 2017-04-19
ES2693080T3 (es) 2018-12-07

Similar Documents

Publication Publication Date Title
ES2426814T3 (es) Mutaciones de K-ras y B-raf y terapia con anticuerpos anti-EGFr
Lee et al. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma
JP6534930B2 (ja) Ｎｔｒｋ３融合体の検出法
WO2014036387A2 (en) Methods for diagnosis and treatment of cancer
KR20150122731A (ko) 암 전이의 예후 및 치료 방법
KR20130064067A (ko) 역형성 림프종 키나아제（ａｌｋ）키나아제 억제제 내성 암의 진단 및 치료용 방법 및 조성물
KR20160061424A (ko) 유방암으로부터 기원하는 골의 전이성 암의 예후 및 치료 방법
JP6149034B2 (ja) 上皮成長因子受容体遺伝子における変異
US20210262037A1 (en) Methods of treating cancer based on identifying mutations in the extracellular domain iii of epidermal growth factor receptor gene
CA2819080A1 (en) Agtr1 as a marker for bevacizumab combination therapies
WO2016189282A1 (en) Method for treatment and prognosis of colorectal cancer
JP4905957B2 (ja) Ｍｎ／ｃａ ｉｘおよび癌予後診断
JP2004533206A (ja) 化学療法のための標的としてのガン関連遺伝子
KR102367595B1 (ko) 상피성 세포 성장 인자 수용체 저해제에 대한 암세포의 내성을 판정하는 방법
EP2858669A1 (en) Autoimmune antibodies
CN103620412B (zh) 作为对表皮生长因子受体治疗剂治疗的响应的预测物的cxcr1
JP6806440B2 (ja) 新規融合体及びその検出法
TW201309806A (zh) Ｖｅｇｆａ基因啟動子中的單一核苷酸多型性及其作為抗－ｖｅｇｆ治療之預測標記的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant